Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients

Cancer Immunology, Immunotherapy

Volumn 56, Issue 11, 2007, Pages 1795-1805

  Alves, Pedro M S ^a,b,c   Viatte, Sebastien ^b,c   Fagerberg, Theres ^b,f   Michielin, Olivier ^b,e,f   Bricard, Gabriel ^a   Bouzourene, Hanifa ^d   Vuilleumier, Henri ^e   Kruger, Thorsten ^e   Givel, Jean Claude ^e   Lévy, Frédéric ^b   Speiser, Daniel E ^a   Cerottini, Jean Charles ^b   Romero, Pedro ^a  

^a Hopital Orthopedique de la Suisse Romande   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Frontiers in Genetics National Center for Competence in Research   (Switzerland)

^d UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

Author keywords

Cancer vaccines; CTL; Tetramers; Tumor immunology

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN 694-702; HLA A ANTIGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL CLONE; CELL LINE; CELL STIMULATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 34548175933     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0323-2     Document Type: Article

References (47)

1. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96
2. Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K (2006) Steap, a prostate tumor antigen, is a target of human CD8(+) T cells. Cancer Immunol Immunother 55:1504-1514
3. Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K (2003) Epha2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 63:8476-8480
4. Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P, Levy F, Speiser DE, Valmori D (2001) Lack of tumor recognition by Htert peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31:2642-2651
5. Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197-2207
6. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G (2003) Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 46:33-57
7. Dupont J, Latouche JB, Ma C, Sadelain M (2005) Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 65:5417-5427
8. Eidelman FJ, Fuks A, DeMarte L, Taheri M, Stanners CP (1993) Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts. J Cell Biol 123:467-475
9. Faure O, Graff-Dubois S, Bretaudeau L, Derre L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K (2004) Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Int J Cancer 108:863-870
10. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809-8814
11. Goldberg AL, Cascio P, Saric T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147-164
12. Graham RA, Wang S, Catalano PJ, Haller DG (1998) Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. Ann Surg 228:59-63
13. Hammarstrom S (1999) The carcinoembryonic antigen (Cea) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67-81
14. Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39:390-396
15. Hernandez J, Lee PP, Davis MM, Sherman LA (2000) The use of HLA A2.1/P53 peptide tetramers to visualize the impact of self tolerance on the Tcr repertoire. J Immunol 164:596-602
16. Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O'Hara CJ, Steele GJ, Thomas P (1993) Carcinoembryonic antigen: eanhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 67:464-470
17. Kreuwel HT, Sherman LA (2001) The T-cell repertoire available for recognition of self-antigens. Curr Opin Immunol 13:639-643
18. Kuroki M, Arakawa F, Matsuo Y, Oikawa S, Misumi Y, Nakazato H, Matsuoka Y (1991) Molecular cloning of nonspecific cross-reacting antigens in human granulocytes. J Biol Chem 266:11810-11817
19. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L (2005) Human Ctl epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 65:6435-6442
20. Marshall J (2003) Carcinoembryonic antigen-based vaccines. Semin Oncol 30:30-36
21. Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, Guillaume P, Cerottini JC, Romero P, Leyvraz S (2005) Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin Exp Immunol 142:292-302
22. Nagel G, Grunert F, Kuijpers TW, Watt SM, Thompson J, Zimmermann W (1993) Genomic organization, splice variants and expression of Cgm1, a CD66-related member of the carcinoembryonic antigen gene family. Eur J Biochem 214:27-35
23. Nap M, Mollgard K, Burtin P, Fleuren GJ (1988) Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 9:145-153
24. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) Gp100/Pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277-286
25. Parham P, Brodsky FM (1981) Partial purification and some properties of Bb7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277-299
26. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175
27. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA (2004) Immunization of patients with the Htert:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10:4688-4698
28. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, Bennink JR, Yewdell JW (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18:343-354
29. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC (2003) Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15:751-763
30. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219
31. Rodeberg DA, Nuss RA, Elsawa SF, Celis E (2005) Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 11:4545-4552
32. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K (2002) Her-2/Neu and HTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906
33. Schirle MKW, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG (2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216-2225
34. Screaton RA, Penn LZ, Stanners CP (1997) Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 137:939-952
35. Shaw AR, Chan JK, Reid S, Seehafer J (1985) Hla-Dr synthesis induction and expression in HLA-Dr-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta. J Natl Cancer Inst 74:1261-1268
36. Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CLJ (1999) Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of Ctl epitopes from Mart-1 and Gp100. Int J Cancer 82:669-677
37. Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P (2004) Ex vivo analysis of human antigen-specific CD8(+) T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma elispot assays for patient immune monitoring. J Immunother 27:298-308
38. Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344-366
39. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K (2000) A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411-3421
40. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/Mart-1 immunodominant peptide analogues. J Immunol 160:1750-1758
41. Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, Cerundolo V, Levy F (1999) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen Mage-3. J Exp Med 189:895-906
42. Van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T (1989) Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 44:634-640
43. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51-64
44. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679
45. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive Ctl from heterogeneous populations using peptide-Mhc tetramers. J Immunol 162:2227-2234
46. Yewdell JW (2001) Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 11:294-297
47. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY (2000) Specific cytolytic T-cell responses to human Cea from patients immunized with recombinant Avipox-Cea vaccine. Clin Cancer Res 6:24-33